Nicotinic Agonist - Drug Development

Drug Development

The development of nicotinic acetylcholine receptor agonists began in the early 1990s after the discovery of nicotine’s positive effects on animal memory. The development of nicotinic acetylcholine receptor agonists has come a long way since then. The nicotinic acetylcholine receptor agonist are gaining increasing attention as drug candidates for multiple central nervous system disorders such as Alzheimer's disease, schizophrenia, attention-deficit hyperactivity disorder (ADHD) and nicotine addiction. Nicotinic acetylcholine receptors are receptors found in the central nervous system, the peripheral nervous systems and skeletal muscles. They are ligand-gated ion channels with binding sites for acetylcholine as well as other agonists. When agonists bind to a receptor it stabilizes the open state of the ion channel allowing influx of cations.

In 2009 there were at least five drugs on the market that affect the nicotinic acetylcholine receptors.

Quinuclidine derivatives
Quinuclidine Carbamates Quinuclidine Amides Quinuclidine Ethers

Read more about this topic:  Nicotinic Agonist

Famous quotes containing the words drug and/or development:

    Behind the steering wheel
    The boy took out his own forehead.
    His girlfriend’s head was a green bag
    Of narcissus stems. “OK you win
    But meet me anyway at Cohen’s Drug Store
    In 22 minutes.”
    John Ashbery (b. 1927)

    The man, or the boy, in his development is psychologically deterred from incorporating serving characteristics by an easily observable fact: there are already people around who are clearly meant to serve and they are girls and women. To perform the activities these people are doing is to risk being, and being thought of, and thinking of oneself, as a woman. This has been made a terrifying prospect and has been made to constitute a major threat to masculine identity.
    Jean Baker Miller (20th century)